Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors

Daniëlle A M Heideman, Peter J F Snijders, Mikael E. Craanen, Elisabeth Bloemena, Chris J L M Meijer, Stefan G M Meuwissen, Victor W. Van Beusechem, Herbert M. Pinedo, David T. Curiel, Hidde J. Haisma, Winald R. Gerritsen

Research output: Contribution to journalArticle

Abstract

Application of recombinant adenoviral vectors for cancer gene therapy is currently limited due to lack of specificity for tumor cells. For gastric and esophageal adenocarcinoma, we present here that the relative abundant expression of the primary adenovirus receptor, coxsackie/adenovirus receptor (CAR), on normal epithelium compared to carcinoma favors the transduction of the epithelium. As such, to achieve specific transduction of cancer cells, targeting approaches are required that ablate the binding of the virus to CAR and redirect the virus to tumor-specific receptors. By immunohistochemistry and reverse transcriptase polymerase chain reaction assays, we demonstrate a marked difference in expression of the human epithelial cell adhesion molecule (EpCAM) between normal and (pre)malignant lesions of the stomach and esophagus. Based on this, we explored the feasibility of using EpCAM to achieve gastric and esophageal adenocarcinoma selective gene transfer. Adenoviral vectors redirected to EpCAM using bispecific antibodies against the adenovirus fiber-knob protein and EpCAM specifically infected gastric and esophageal cancer cell lines. Using primary human cells, an improved ratio of tumor transduction over normal epithelium transduction was accomplished by the EpCAM-targeted vectors. This study thus indicates that EpCAM-targeted adenoviral vectors may be useful for gastric and esophageal cancer-specific gene therapy in patients.

Original languageEnglish (US)
Pages (from-to)342-351
Number of pages10
JournalCancer Gene Therapy
Volume8
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Stomach
Adenocarcinoma
Coxsackie and Adenovirus Receptor-Like Membrane Protein
Genes
Epithelium
Neoplasm Genes
Esophageal Neoplasms
Genetic Therapy
Stomach Neoplasms
Bispecific Antibodies
Virus Attachment
Neoplasms
Oncogenic Viruses
Reverse Transcriptase Polymerase Chain Reaction
Esophagus
Epithelial Cell Adhesion Molecule
Immunohistochemistry
Carcinoma
Cell Line

Keywords

  • Coxsackie/adenovirus receptor
  • Epithelial cell adhesion molecule
  • Gastric and esophageal cancer
  • Gene therapy
  • Tumor marker
  • Vector targeting

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Heideman, D. A. M., Snijders, P. J. F., Craanen, M. E., Bloemena, E., Meijer, C. J. L. M., Meuwissen, S. G. M., ... Gerritsen, W. R. (2001). Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Therapy, 8(5), 342-351. https://doi.org/10.1038/sj.cgt.7700313

Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. / Heideman, Daniëlle A M; Snijders, Peter J F; Craanen, Mikael E.; Bloemena, Elisabeth; Meijer, Chris J L M; Meuwissen, Stefan G M; Van Beusechem, Victor W.; Pinedo, Herbert M.; Curiel, David T.; Haisma, Hidde J.; Gerritsen, Winald R.

In: Cancer Gene Therapy, Vol. 8, No. 5, 2001, p. 342-351.

Research output: Contribution to journalArticle

Heideman, DAM, Snijders, PJF, Craanen, ME, Bloemena, E, Meijer, CJLM, Meuwissen, SGM, Van Beusechem, VW, Pinedo, HM, Curiel, DT, Haisma, HJ & Gerritsen, WR 2001, 'Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors', Cancer Gene Therapy, vol. 8, no. 5, pp. 342-351. https://doi.org/10.1038/sj.cgt.7700313
Heideman, Daniëlle A M ; Snijders, Peter J F ; Craanen, Mikael E. ; Bloemena, Elisabeth ; Meijer, Chris J L M ; Meuwissen, Stefan G M ; Van Beusechem, Victor W. ; Pinedo, Herbert M. ; Curiel, David T. ; Haisma, Hidde J. ; Gerritsen, Winald R. / Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. In: Cancer Gene Therapy. 2001 ; Vol. 8, No. 5. pp. 342-351.
@article{16fd3433c48d445e8511b9061eb7f7e7,
title = "Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors",
abstract = "Application of recombinant adenoviral vectors for cancer gene therapy is currently limited due to lack of specificity for tumor cells. For gastric and esophageal adenocarcinoma, we present here that the relative abundant expression of the primary adenovirus receptor, coxsackie/adenovirus receptor (CAR), on normal epithelium compared to carcinoma favors the transduction of the epithelium. As such, to achieve specific transduction of cancer cells, targeting approaches are required that ablate the binding of the virus to CAR and redirect the virus to tumor-specific receptors. By immunohistochemistry and reverse transcriptase polymerase chain reaction assays, we demonstrate a marked difference in expression of the human epithelial cell adhesion molecule (EpCAM) between normal and (pre)malignant lesions of the stomach and esophagus. Based on this, we explored the feasibility of using EpCAM to achieve gastric and esophageal adenocarcinoma selective gene transfer. Adenoviral vectors redirected to EpCAM using bispecific antibodies against the adenovirus fiber-knob protein and EpCAM specifically infected gastric and esophageal cancer cell lines. Using primary human cells, an improved ratio of tumor transduction over normal epithelium transduction was accomplished by the EpCAM-targeted vectors. This study thus indicates that EpCAM-targeted adenoviral vectors may be useful for gastric and esophageal cancer-specific gene therapy in patients.",
keywords = "Coxsackie/adenovirus receptor, Epithelial cell adhesion molecule, Gastric and esophageal cancer, Gene therapy, Tumor marker, Vector targeting",
author = "Heideman, {Dani{\"e}lle A M} and Snijders, {Peter J F} and Craanen, {Mikael E.} and Elisabeth Bloemena and Meijer, {Chris J L M} and Meuwissen, {Stefan G M} and {Van Beusechem}, {Victor W.} and Pinedo, {Herbert M.} and Curiel, {David T.} and Haisma, {Hidde J.} and Gerritsen, {Winald R.}",
year = "2001",
doi = "10.1038/sj.cgt.7700313",
language = "English (US)",
volume = "8",
pages = "342--351",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors

AU - Heideman, Daniëlle A M

AU - Snijders, Peter J F

AU - Craanen, Mikael E.

AU - Bloemena, Elisabeth

AU - Meijer, Chris J L M

AU - Meuwissen, Stefan G M

AU - Van Beusechem, Victor W.

AU - Pinedo, Herbert M.

AU - Curiel, David T.

AU - Haisma, Hidde J.

AU - Gerritsen, Winald R.

PY - 2001

Y1 - 2001

N2 - Application of recombinant adenoviral vectors for cancer gene therapy is currently limited due to lack of specificity for tumor cells. For gastric and esophageal adenocarcinoma, we present here that the relative abundant expression of the primary adenovirus receptor, coxsackie/adenovirus receptor (CAR), on normal epithelium compared to carcinoma favors the transduction of the epithelium. As such, to achieve specific transduction of cancer cells, targeting approaches are required that ablate the binding of the virus to CAR and redirect the virus to tumor-specific receptors. By immunohistochemistry and reverse transcriptase polymerase chain reaction assays, we demonstrate a marked difference in expression of the human epithelial cell adhesion molecule (EpCAM) between normal and (pre)malignant lesions of the stomach and esophagus. Based on this, we explored the feasibility of using EpCAM to achieve gastric and esophageal adenocarcinoma selective gene transfer. Adenoviral vectors redirected to EpCAM using bispecific antibodies against the adenovirus fiber-knob protein and EpCAM specifically infected gastric and esophageal cancer cell lines. Using primary human cells, an improved ratio of tumor transduction over normal epithelium transduction was accomplished by the EpCAM-targeted vectors. This study thus indicates that EpCAM-targeted adenoviral vectors may be useful for gastric and esophageal cancer-specific gene therapy in patients.

AB - Application of recombinant adenoviral vectors for cancer gene therapy is currently limited due to lack of specificity for tumor cells. For gastric and esophageal adenocarcinoma, we present here that the relative abundant expression of the primary adenovirus receptor, coxsackie/adenovirus receptor (CAR), on normal epithelium compared to carcinoma favors the transduction of the epithelium. As such, to achieve specific transduction of cancer cells, targeting approaches are required that ablate the binding of the virus to CAR and redirect the virus to tumor-specific receptors. By immunohistochemistry and reverse transcriptase polymerase chain reaction assays, we demonstrate a marked difference in expression of the human epithelial cell adhesion molecule (EpCAM) between normal and (pre)malignant lesions of the stomach and esophagus. Based on this, we explored the feasibility of using EpCAM to achieve gastric and esophageal adenocarcinoma selective gene transfer. Adenoviral vectors redirected to EpCAM using bispecific antibodies against the adenovirus fiber-knob protein and EpCAM specifically infected gastric and esophageal cancer cell lines. Using primary human cells, an improved ratio of tumor transduction over normal epithelium transduction was accomplished by the EpCAM-targeted vectors. This study thus indicates that EpCAM-targeted adenoviral vectors may be useful for gastric and esophageal cancer-specific gene therapy in patients.

KW - Coxsackie/adenovirus receptor

KW - Epithelial cell adhesion molecule

KW - Gastric and esophageal cancer

KW - Gene therapy

KW - Tumor marker

KW - Vector targeting

UR - http://www.scopus.com/inward/record.url?scp=0034917310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034917310&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700313

DO - 10.1038/sj.cgt.7700313

M3 - Article

C2 - 11477454

AN - SCOPUS:0034917310

VL - 8

SP - 342

EP - 351

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 5

ER -